104 related articles for article (PubMed ID: 38941606)
21. Intertwining roles of circadian and metabolic regulation of the innate immune response.
Cox SL; O'Siorain JR; Fagan LE; Curtis AM; Carroll RG
Semin Immunopathol; 2022 Mar; 44(2):225-237. PubMed ID: 35022891
[TBL] [Abstract][Full Text] [Related]
22. Phagocytosis checkpoints as new targets for cancer immunotherapy.
Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL
Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760
[TBL] [Abstract][Full Text] [Related]
23. Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on Innate Immunity.
Dengler V; Westphalen K; Koeppen M
Curr Pharm Des; 2015; 21(24):3469-76. PubMed ID: 26144943
[TBL] [Abstract][Full Text] [Related]
24. Principles of immunotherapy.
Olszanski AJ
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):670-2. PubMed ID: 25995426
[TBL] [Abstract][Full Text] [Related]
25. Innate Immune Stimulation in Cancer Therapy.
Düwell P; Heidegger S; Kobold S
Hematol Oncol Clin North Am; 2019 Apr; 33(2):215-231. PubMed ID: 30832996
[TBL] [Abstract][Full Text] [Related]
26. Chronopharmacological strategies focused on chrono-drug discovery.
Ohdo S; Koyanagi S; Matsunaga N
Pharmacol Ther; 2019 Oct; 202():72-90. PubMed ID: 31173839
[TBL] [Abstract][Full Text] [Related]
27. Sleep, immunity, and circadian clocks: a mechanistic model.
Bollinger T; Bollinger A; Oster H; Solbach W
Gerontology; 2010; 56(6):574-80. PubMed ID: 20130392
[TBL] [Abstract][Full Text] [Related]
28. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
29. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
30. Circadian rhythms in immunity and host-parasite interactions.
Hunter FK; Butler TD; Gibbs JE
Parasite Immunol; 2022 Mar; 44(3):e12904. PubMed ID: 34971451
[TBL] [Abstract][Full Text] [Related]
31. Circadian rhythm regulation in the immune system.
Ding J; Chen P; Qi C
Immunology; 2024 Apr; 171(4):525-533. PubMed ID: 38158836
[TBL] [Abstract][Full Text] [Related]
32. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
33. Systems biology applied to vaccine and immunotherapy development.
Buonaguro L; Wang E; Tornesello ML; Buonaguro FM; Marincola FM
BMC Syst Biol; 2011 Sep; 5():146. PubMed ID: 21933421
[TBL] [Abstract][Full Text] [Related]
34. Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?
Karaboué A; Innominato PF; Wreglesworth NI; Duchemann B; Adam R; Lévi FA
Br J Cancer; 2024 Jun; ():. PubMed ID: 38834742
[TBL] [Abstract][Full Text] [Related]
35. A circadian clock in macrophages controls inflammatory immune responses.
Keller M; Mazuch J; Abraham U; Eom GD; Herzog ED; Volk HD; Kramer A; Maier B
Proc Natl Acad Sci U S A; 2009 Dec; 106(50):21407-12. PubMed ID: 19955445
[TBL] [Abstract][Full Text] [Related]
36. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
37. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
Rivera Vargas T; Benoit-Lizon I; Apetoh L
Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
[TBL] [Abstract][Full Text] [Related]
38. Immune Cell-Derived Extracellular Vesicles - New Strategies in Cancer Immunotherapy.
Yang P; Peng Y; Feng Y; Xu Z; Feng P; Cao J; Chen Y; Chen X; Cao X; Yang Y; Jie J
Front Immunol; 2021; 12():771551. PubMed ID: 34956197
[TBL] [Abstract][Full Text] [Related]
39. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
40. Chrono-tailored drug delivery systems: recent advances and future directions.
Butler CT; Rodgers AM; Curtis AM; Donnelly RF
Drug Deliv Transl Res; 2024 Jul; 14(7):1756-1775. PubMed ID: 38416386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
